Ninety-one women (mean age, 32 years) at 14 centers in Canada and Australia were randomly assigned to start hybrid closed-loop insulin therapy with Control-IQ technology by 16 weeks’ gestation ...

Time in range increased from 60.5% at baseline to 66.5% during the antenatal period with the hybrid closed-loop system, whereas the control group had a time in range increase from 57.6% at ...